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Introduction
Hemostasis monitoring is becoming increasingly important in the management of
bleeding patients in the operating room (OR) and the intensive care unit (ICU) in
order to improve outcome and reduce costs of treatment. It has been shown in car-
diac surgery that frequent reassessment of the coagulation status and transfusion
according to well-structured algorithms reduced blood loss and blood component
use when compared with transfusion regimens based on clinician discretion [1, 2].
Routine laboratory based coagulation tests (e.g., prothrombin time [PT]/interna-
tional normalized ratio [INR], activated partial thromboplastin time [aPTT], fibrin-
ogen) measure clotting times and factors in recalcified plasma after activation with
different coagulation activators. Platelet numbers are given to complete overall coag-
ulation assessment. Although the values obtained by routine coagulation testing are
accurate, standardized, and have been used for a long time, their use has been ques-
tioned in the assessment of a severely bleeding patient because values are measured
in plasma, no information on platelet function is available, and there is a time delay
of 30–60 min from sampling to obtaining the results.
Point-of-care coagulation monitoring may overcome several limitations of routine
coagulation testing. Blood is analyzed at the ‘bedside’ close to the patient and not
necessarily in the central laboratory. The coagulation status is assessed in whole
blood, better describing physiological clot development by letting the plasma coagu-
lation system interact with platelets and red blood cells (RBCs). Therefore, these
techniques may also provide useful information on platelet function. Furthermore,
results are available earlier and clot development can be visually displayed real-time
using certain devices. According to their main objective and function, point-of-care
coagulation analyzers can be classified as follows: Instruments analyzing plasmatic
coagulation (e.g., activated clotting time [ACT] or heparin management devices [3]),
platelet function (e.g., Platelet Function Analyzer [PFA]-100® [4]), and techniques
assessing combined plasmatic coagulation, platelet function, and fibrinolytic system
(viscoelastic techniques: Sonoclot® and TEG®/ROTEM® ).
This chapter focuses on viscoelastic techniques for perioperative coagulation
monitoring of the critically ill patient. The basic principles and properties of the dif-
ferent techniques are summarized, their clinical use is outlined, and the specific
ability to monitor different pharmacological substances that interact with hemosta-
sis is presented. Viscoelastic techniques for measuring coagulation have also been
used in the hemostasis laboratory for coagulation testing of certain hemostatic dis-
orders or syndromes, but this goes beyond the scope of the current chapter.
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c
Fig. 1. Viscoelastic point of care coagulation
devices a Sonoclot®; b TEG®; c ROTEM®
Sonoclot Analysis
The Sonoclot Analyzer (Fig. 1a, Sonoclot® Coagulation & Platelet Function Analyzer,
Sienco Inc., Arvada, CO) was introduced in 1975 by von Kaulla et al. [5]. The princi-
ple of the Sonoclot analysis has been described recently in detail [6]. Briefly, Sonoc-
lot measurements are based on the detection of viscoelastic changes of a whole
blood or plasma sample. To start a measurement, a hollow, open ended, disposable
plastic probe is mounted on the transducer head. Then, 360 µl of test sample is
added to the cuvette containing different coagulation activators/inhibitors and cal-
cium (to recalcify citrated blood samples). After an automated mixing procedure,
the probe is immersed into the sample and oscillates vertically in the sample. The
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Fig. 2. Working principles of viscoelastic point of care coagulation devices. a Sonoclot®: Blood sample in
cuvette (1) containing activator (2), disposable plastic probe (3) oscillating in blood sample mounted on
electromechanical transducer head (4), data processing (5). b TEG®: rotating cup with blood sample (1),
coagulation activator (2), pin and torsion wire (3), electromechanical transducer (4), data processing (5).
c ROTEM®: Cuvette with blood (1), activator added by pipetting (2), pin and rotating axis (3), electrome-
chanical signal detection via light source and mirror mounted on axis (4), data processing (5). For detailed
description see text.
changes in impedance to movement imposed by the developing clot are measured
(Fig. 2a). Different cuvettes with different coagulation activators/inhibitors are com-
mercially available (Table 1). Normal values for tests run by the Sonoclot Analyzer
depend largely on the type of sample (whole blood versus plasma, native versus
citrated sample) and type of cuvette used (Table 2).
The Sonoclot Analyzer provides information on the entire hemostasis process,
both in a qualitative graph, known as the Sonoclot Signature (Fig. 3) and as quanti-
tative results: The ACT, the clot rate (CR) and the platelet function (PF). The ACT is
the time in seconds from the activation of the sample until the beginning of fibrin
formation. This onset of clot formation is defined as a certain upward deflection of
the Sonoclot Signature and is detected automatically by the machine. Sonoclot’s ACT
corresponds to the conventional ACT measurement, provided that cuvettes contain-
ing a high concentration of typical activators (celite, kaolin) are being used [7–9].
The CR, expressed in Units/min, is the maximum slope of the Sonoclot Signature
during initial fibrin polymerization and clot development. Values representing phys-
iologic condition as a function of the activator used are listed in Table 2. PF is
reflected by the timing and quality of the clot retraction. PF is a calculated value,
derived by using an automated numeric integration of changes in the Sonoclot Sig-
nature after fibrin formation has completed (see manufacturer’s reference). In order
to obtain reliable results for PF, cuvettes containing glass beads for specific platelet
activation (gbACT+) should be used [10]. The nominal range of values for the PF
goes from 0, representing no PF (no clot retraction and flat Sonoclot Signature after
fibrin formation), to approximately 5, representing strong PF (clot retraction occurs
sooner and is very strong, with clearly defined, sharp peaks in the Sonoclot Signa-
ture after fibrin formation).
The Sonoclot Analyzer has been criticized because its results are influenced by
age, sex, and platelet count [11]. Additionally, studies showed poor reproducibility of
some of the measured parameters, especially CR and PF [12, 13]. However, others
found the Sonoclot Analyzer to be valuable and reliable in patients undergoing car-
diac surgical procedures [14, 15] and the Sonoclot Analyzer has even demonstrated
a precision close to that of thrombelastography [16]. In more recent studies, test var-
iability of ACT values determined by Sonoclot were comparable to other established
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Sonoclot® Coagulation and Platelet Function Analyzer
SonACT Celite High dose heparin management without aprotinin
kACT Kaolin High dose heparin management with/without aprotinin
aiACT Celite
+ Clay
High dose heparin management with aprotinin (aprotinin-insensitive
ACT)
gbACT+ Glass beads Overall coagulation and platelet function assessment
H-gbACT+ Glass beads
+ Heparinase
Overall coagulation and platelet function assessment in presence of
heparin; detection of heparin
microPT* 1:1000 TF Extrinsic pathway; monitoring recombinant activated factor VIIa
Native None Non-activated assay
Also used to run custom hemostasis tests
Thrombelastograph Hemostasis system (TEG®)
Kaolin Kaolin Overall coagulation assessment and platelet function
Heparinase Kaolin
+ Heparinase
Specific detection of heparin (modified Kaolin test adding hepari-





Platelet function, monitoring antiplatelet therapy (aspirin, ADP-,
GPIIb/IIIa inhibitors)
Native None Non-activated assay
Also used to run custom hemostasis tests
Rotation Thrombelastometry (ROTEM®)
EXTEM TF Extrinsic pathway; fast assessment of clot formation and fibrinolysis




Qualitative assessment of fibrinogen levels
APTEM TF
+ Aprotinin
Fibrinolytic pathway; fast detection of fibrinolysis when used
together with EXTEM
HEPTEM Contact activator +
Heparinase
Specific detection of heparin (modified INTEM test adding hepari-
nase to inactivate present heparin)
ECATEM Ecarin Management of direct thrombin inhibitors (e.g., hirudin, argatroban)
TIFTEM* 1:1000 TF Extrinsic pathway; monitoring recombinant activated factor VIIa
NATEM None Non-activated assay
Also used to run custom hemostasis tests
ACT: activated clotting time; TF: tissue factor; ADP: adenosine diposphate; GPIIb/IIIa: glycoprotein IIb/IIIa
receptor. *For research use only (not yet on the market in 2006).
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Table 2. Reference values for Sono-




SonACT 85–145 sec 15–45 Clot Signal Units/min
kACT 94–178 sec 15–33 Clot Signal Units/min
gbACT+ 119–195 sec 7–23 Clot Signal Units/min
aiACT 62–93 sec 22–41 Clot Signal Units/min
For specific details on assays, see
Table 1.
Fig. 3. Typical Sonoclot® Signature
ACT: activated clotting time; CR: clot
rate; PF: platelet function.
ACT analyzers (8–9% on average) [7–9]. Furthermore, test variability for PF deter-
mined by gbACT+ and H-gbACT+ (heparinase glass-bead test) was 6–10% in a
recent study assessing PF after administration of the glycoprotein IIb/IIIa (GPIIb/
IIIa) antagonist, tirofiban, with or without heparin [10].
Thrombelastography, Thrombelastometry
Thrombelastography is a method to assess overall coagulation function and was first
described by Hartert in 1948 [17]. Because the thrombelastograph measures the
shear elasticity of the blood sample, thrombelastography is sensitive to all interact-
ing cellular and plasmatic components such as coagulation and fibrinolysis. The
thrombelastograph measures and graphically displays the time until initial fibrin
formation, the kinetics of fibrin formation and clot development, and the ultimate
strength and stability of the fibrin clot as well as fibrinolysis. In the earlier literature,
the terms thrombelastography, thrombelastograph and TEG were used generically.
However, in 1996, thrombelastograph® and TEG® became a registered trademark of
the Hemoscope Corporation (Niles, IL, USA) and from that time on these terms
have been employed to describe the assay performed using Hemoscope instrumen-
tation only. Alternatively, Pentapharm GmbH (Munich, Germany) markets a modi-
fied instrumentation using the terminology rotation thrombelastometry, ROTEM®.
The TEG® (Fig. 1b) measures the clot’s physical property by the use of a station-
ary cylindrical cup that holds the blood sample and is oscillated through an angle of
4°45’. Each rotation cycle lasts 10 seconds. A pin is suspended in the blood by a tor-
sion wire and is monitored for motion (Fig. 2b). The torque of the rotation cup is
transmitted to the immersed pin only after fibrin-platelet bonding has linked the
cup and pin together. The strength of these fibrin-platelet bonds affects the magni-
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Fig. 4. Typical TEG/ROTEM® tracing. R: reaction time; K: kinetics; [ : slope between R and K; MA: maximum
amplitude; CL: clot lysis; CT: clotting time; CFT: clot formation time; [ : slope of tangent at 2 mm ampli-
tude; MCF: maximal clot firmness; LY: Lysis. For detailed description and reference values please see Tables
2 and 3.
tude of the pin motion. Thus, the output is directly related to the strength of the
formed clot. As the clot retracts or lyses, these bonds are broken and the transfer of
cup motion is again diminished. The rotation movement of the pin is converted by
a mechanical-electrical transducer to an electrical signal finally being displayed as
the typical TEG® tracing (Fig. 4). The ROTEM® technology (Fig. 1c) avoids some
limitations of traditional instruments for thrombelastography, especially the suscep-
tibility to mechanical shocks. Signal transmission of the pin suspended in the blood
sample is carried out via an optical detector system, not a torsion wire and the
movement is initiated from the pin, not the cup (Fig. 2c).
Most common tests for both technologies are listed in Table 1. The TEG® and
ROTEM® technology are comparable and show similar tracings (Fig. 4) but nomen-
clature and reference ranges are different (Table 3). The repeatability of measure-
ments by both devices has been shown to be acceptable, provided they are per-
formed exactly as outlined in the user manuals. For example, coefficients of varia-
tion using kaolin activated TEG® were 13% for reaction time (R), 4% for kinetics
(K), 3% for [ , and 6% for maximum amplitude (MA) (TEG® 5000 User Manual)
and 3–12% for coagulation time (CT) and clot formation time (CFT, intrinsic-,
extrinsic-TEM), 1–5% for [ and maximum clot firmness (MCF, intrinsic-, extrinsic-
TEM), and 6–13% for MCF (fibrinogen [FIB]-TEM) [18].
Comparing Viscoelastic Techniques with Standard Hemostatic
Laboratory Tests
Conventional laboratory coagulation tests are usually performed in plasma and
most typically end when fibrin strands are formed. However, viscoelastic tests are
whole blood assays measuring the entire clotting process from fibrin formation to
clot retraction and lysis. Several studies have compared results from viscoelastic
techniques to laboratory coagulation data. It is not surprising that point-of-care
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(period to 2 mm amplitude)
R (reaction time)
N (WB) 4–8 min
N (Cit) 3–8 min
CT (clotting time)
N (Cit, INTEM) 137–246 sec
N (Cit, EXTEM) 42–74 sec
Clot kinetics
(period from 2 to 20 mm
amplitude)
K (kinetics)
N (WB) 1–4 min
N (Cit) 1–3 min
CFT (clot formation time)
N (Cit, INTEM) 40–100 sec
N (Cit, EXTEM) 46–148 sec
Clot strengthening
(alpha angle)
[ (slope between r and k)
N (WB) 47–74 °
N (Cit) 55–78 °
[ (slope of tangent at 2mm amplitude)
N (Cit, INTEM) 71–82°
N (Cit, EXTEM) 63–81°
Amplitude (at set time) A A
Maximum strength MA (maximum amplitude)
N (WB) 55–73 mm
N (Cit) 51–69 mm
MCF (maximum clot firmness)
N (Cit, INTEM) 52–72 mm
N (Cit, EXTEM) 49–71 mm
N (Cit, FIBTEM) 9–25 mm
Lysis (at fixed time) CL30, CL60 LY30, LY60
TEG®: N=normal values for kaolin activated TEG® in native whole blood (WB) or citrated and recalcified
blood samples (Cit) (Hemoscope Corp.). ROTEM®: N=normal values for contact (INTEM), tissue factor
(EXTEM) and tissue factor plus GPIIb/IIIa inhibitor (FIBTEM) activated citrated and recalcified blood samples
[18]. Reference values depend on reference population, blood sampling technique, other pre-analytical fac-
tors and coagulation activator.
clotting times (ACT, R, CT) showed a trend in the same direction as laboratory
based clotting times, depending on the activator used. Therefore, a whole blood
sample from a heparinized patient or a patient with hemophilia (factor VIII or IX
deficiency) will show a significantly prolonged CT if a contact activator is used.
However, there is a more obvious association between the maximum strength MA/
MCF of the TEG/ROTEM® signature and both platelet count (or function) and
fibrinogen concentration [19, 20]. To finally determine the fibrinogen influence, tests
can be performed eliminating platelet function by a GPIIb/IIIa inhibitor (e.g., fib-
TEM). This concept has been proven to work and a good correlation of this modi-
fied MA/MCF with fibrinogen levels determined by the Clauss method has been
shown (r=0.85 [TEG® 5000 User Manual] and r=0.75 [21]).
Cardiac Surgery and Postoperative Care
Coagulation management of patients undergoing cardiac surgery is complex because
of a delicate balance between anticoagulation for cardiopulmonary bypass (CPB)
and hemostasis after CPB. During CPB, optimal anticoagulation dictates that coagu-
lation is antagonized and platelets are prevented from activation so that microvascu-
lar clots do not form on the extracorporeal circuit. After surgery, coagulation abnor-
malities, platelet dysfunction, and fibrinolysis can occur, creating a situation
whereby hemostatic integrity must be restored. The complex process of anticoagula-
tion with heparin, antagonism with protamine, and postoperative hemostasis ther-
apy cannot be performed without careful and accurate monitoring.
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ACT is currently used in clinical practice to monitor heparin therapy during CPB
correlating well with heparin concentration, mainly before going on CPB [7–9, 22].
The Sonoclot Analyzer, measuring the ACT, has been used to guide heparin manage-
ment for CPB in the presence or absence of aprotinin and the accuracy and perfor-
mance has been shown to be comparable to standard ACT machines [7–9]. Further-
more, the Sonoclot Analyzer has been shown to reliably detect pharmacological
GPIIb/IIIa inhibition [10, 23] and successfully used to assess the coagulation status
and platelet function in patients undergoing cardiac surgery [14].
Viscoelastic point-of-care coagulation devices have been applied, with limited
success, to predict excessive bleeding after CPB [24, 25]. However, large prospective
[1] and retrospective studies [26] have demonstrated a significant decrease in peri-
operative and overall transfusion requirement if hemostasis management was
guided by TEG®/ROTEM® based algorithms. Interestingly, a recent study by Avidan
et al. showed little advantage of a combined transfusion algorithm using TEG®
(global coagulation), PFA-100® (platelet function), and Hepcon® (heparinization),
over a well-structured laboratory-guided algorithm. Both approaches were able to
reduce postoperative blood component usage compared with clinical discretion
alone [2].
To detect non-heparin related hemostatic problems even in the presence of large
amounts of heparin during CPB, tests with heparinase have been developed for each
instrument (Table 1) and an algorithm based upon heparinase-modified TEG®
resulted in a significant reduction in hemostatic products [27].
Hepatic Surgery and Postoperative Care
Patients undergoing hepatic surgery and, particularly, orthotopic liver transplanta-
tion may have large derangements in their coagulation making point-of-care coagu-
lation monitoring highly desirable. Problems associated with the defective organ
(decreased synthesis and clearance of clotting factors, platelet defects) lead to
impaired hemostasis and hyperfibrinolysis. Furthermore, systemic complications
like sepsis and disseminated intravascular coagulation (DIC) further complicate a
pre-existing coagulopathy. Finally, marked changes in hemostasis in orthotopic liver
transplantation occur during the anhepatic phase and immediately following organ
reperfusion, mainly a hyperfibrinolysis resulting from accumulation of tissue plas-
minogen activator due to inadequate hepatic clearance and a release of exogenous
heparin and endogenous heparin-like substances.
One of the first clinical applications of TEG® was in the hemostatic management
of orthotopic liver transplantation and TEG® guided component replacement [19].
Although the value of TEG/ROTEM® in management of patients undergoing ortho-
topic liver transplantation has been established in the literature [28, 29], only a third
of all orthotopic liver transplantation programs in the United States used TEG® rou-
tinely according to a national survey in 2002 [30]. In addition to the hemorrhagic
risk associated with hepatic surgery and orthotopic liver transplantation, hypercoag-
ulability and thrombotic complications have been described in the postoperative
period and can be adequately assessed with TEG/ROTEM® [31, 32]. Only a few stud-
ies are available on the use of the Sonoclot Analyzer in hepatic surgery and ortho-
topic liver transplantation; however, this technique has been found to be useful in
the perioperative coagulation management of these patients [33].
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Other Applications of Viscoelastic Point-of-care Coagulation
Monitoring
Viscoelastic techniques have been used to assess blood coagulation in multiple clin-
ical situations outside the cardiac and hepatic units, but experience is limited. For
example, TEG® has been applied to measure the coagulation status in trauma
patients [34]. Furthermore, TEG/ROTEM® and Sonoclot® have been used to assess
a hypercoagulable state in several clinical settings, e.g., after major abdominal sur-
gery [35], in obstetrics [36], and in uremic patients undergoing a surgical proce-
dure [37]. Finally, there is a long list of publications on the successful use of TEG/
ROTEM® and Sonoclot® in other clinical areas, summarized in recent reviews [6,
38, 39].
Monitoring Anticoagulants
ACT measurements to guide heparin therapy and the use of modified point-of-care
coagulation tests with heparinase to assess the coagulation status in the absence of
the anti-coagulatory effects of heparin have been described above. However, besides
the monitoring of unfractioned heparin, studies have shown that treatment with low
molecular weight heparin (LMWH) and heparinoids (e.g., danaparoid) can also be
assessed with point-of-care viscoelastic tests [40]. Both standard and heparinase-
modified tests have to be performed in order to increase the sensitivity of TEG/
ROTEM® for the effects of LMWH and heparinoids.
Direct thrombin inhibitors are increasingly being used for different indications.
Point-of-care viscoelastic techniques, especially the ecarin clotting time (ecarin
directly activates thrombin) are helpful in the assessment of the effects of direct
thrombin inhibitors [41].
Platelets play a key role in overall coagulation and assessment of their function is
highly desirable (more than the platelet number). Anti-platelet agents typically act
to inhibit cyclo-oxygenase 1 (e.g., aspirin [acetylsalicylic acid]), ADP receptors (e.g.,
clopidogrel), or GPIIb/IIIa receptors (e.g., abciximab, tirofiban). As mentioned
above, the Sonoclot Analyzer has been shown to reliably detect pharmacological
GPIIb/IIIa inhibition [10, 23]. Furthermore, the MA/MCF from TEG/ROTEM® gives
some information on overall platelet function (and fibrinogen levels), but is not sen-
sitive to targeted pharmacological inhibition. Therefore, a more sophisticated and
laborious test has been developed recently for the TEG® (PlateletMapping) using
arachidonic acid and ADP to selectively activate platelets and determine platelet
function in the presence of anti-platelet therapy [42].
Monitoring Pro-Coagulant Therapy
Maintaining an adequate coagulation status is one of the goals in patients with
severe hemorrhage besides preserving sufficient blood volume and oxygen carrying
capacity. Strategies to support coagulation are based on the underlying cause of
bleeding and range from prevention of hypothermia and acidosis, re-warming,
transfusion of blood products, selective administration of coagulation factors, and
the use of pharmacological agents. Interactions of administered crystalloids and col-
loids with coagulation have to be considered. For example, progressive hemodilution
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with current hydroxyethyl starch solutions still compromises blood coagulation
more than gelatin or albumin solutions [43].
Modern practice of coagulation management is based on the concept of specific
component therapy and requires rapid diagnosis and monitoring of the pro-coagu-
lant therapy (i.e., clotting times, clot kinetics, and clot strengthening). Fibrinogen is
a key coagulation factor (substrate to form a clot) and isolated fibrinogen substitu-
tion in severe models of dilutional coagulopathy has been shown to improve clot
strength and reduce blood loss [44]. Supplementary administration of prothrombin
complex (concentrates of factor II, VII, IX, X, antithrombin III, protein C) addition-
ally improved initiation of coagulation and reversed the dilutional coagulopathy
[45]. Fibrinogen levels can be assessed by measuring clot strength (MCF/MA) in
presence of platelet inhibition by a GPIIb/IIIa inhibitor (e.g., FIBTEM) [21] or by
assessing Sonoclot’s CR [46]. Fibrinogen substitution should be considered in a
bleeding patient if MCF levels are lower than 9 mm in a FIBTEM test.
Recombinant activated factor VII (rFVIIa) treatment is currently approved for
patients with congenital or acquired hemophilia, factor VII deficiency, and Glanz-
mann’s thrombasthenia. However, factor VIIa is increasingly used in off-label indica-
tions to control severe bleeding (e.g., major trauma, surgical interventions, intrace-
rebral hemorrhage). The concept is to locally activate the coagulation at sites of tis-
sue factor exposure. The resulting thrombin burst then leads to the formation of a
fibrin clot, provided there are sufficient fibrinogen levels. Consensus guidelines have
been published for these off-label indications, but it is still unclear how to reliably
monitor patients receiving recombinant factor VIIa (rVIIa) [47]. In order to study
thrombin generation, modified TEG/ROTEM® parameters (based on the original
tracing) have been introduced recently: Maximum velocity of clot formation (maxi-
mum rate of thrombus generation, MaxVel), time to reach MaxVel (time to maxi-
mum thrombus generation, tMaxVel), and total thrombus generation (area under
the curve, TTG) [48]. These parameters are supposed to be more sensitive to rVIIa
than standard TEG/ROTEM® parameters and dilute tissue factor should be used as
coagulation activator for best sensitivity [39]. In a preliminary study, we were able
to monitor the effects of rVIIa in vitro after severe hemodilution using the new
diluted tissue factor activated tests from Sonoclot (microPT) and the ROTEM® (TIF-
TEM) [46, 49].
Factor XIII is needed for cross-linking fibrin, therefore, stabilizing the clot,
increasing clot strength and resistance to fibrinolysis. There are case reports on
patients with unexplained intraoperative bleeding due to decreased factor XIII and
subsequent stabilization after substitution. Impaired clot strength and increased
lysis have been observed [50].
Antifibrinolytic drugs (aprotinin, tranexamic and epsilon aminocaproic acid) are
used mostly in complex cardiac surgery to reduce bleeding and transfusion require-
ments. Aprotinin may interact with point-of-care coagulation assays, prolonging for
example celite-activated ACT tests. Therefore, kaolin or aprotinin-insensitive ACT
should be used to guide heparin therapy in these patients [8, 9]. Antifibrinolytic
therapy may be predicted in vitro in TEG/ROTEM® with certain tests already con-
taining an antifibrinolytic agent (e.g., APTEM). APTEM predictive of a good patient
response would then show a significantly improved initiation/propagation phase
compared to EXTEM and or disappearance of signs of hyperfibrinolysis. There are
no conclusive studies on monitoring desmopressin (DDAVP) therapy so far.
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Problems with Point-of-Care Coagulation Monitoring
Several concerns have been raised using viscoelastic point-of-care coagulation tests
because these tests are hard to standardize. The blood collection site, processing of
the sample (native versus citrated samples, time delay between collection and mea-
surement – for citrated samples a minimum rest time of 30 min is required), patient
age and gender may significantly affect the results of these tests [38]. Furthermore,
equipment, activators, and other modifications will alter the assay specificity. All
these factors have to be considered when interpreting results in the literature and
have to be known and standardized when running tests in a single center.
As with all point-of-care devices, there is a concern that the devices are not ade-
quately maintained and that quality controls are not done on a regular basis. Using
such an instrument for decision making in patient care may harm the patient
because of the possibility of incorrectly measured data. Furthermore, non-labora-
tory personnel are running these point-of-care tests, which may lead to further
errors, if not adequately trained. In an effort to minimize these problems and release
the OR/ICU personnel from the burden of maintaining their devices, point-of-care
devices have to be at least supervised by the central laboratory. Alternatively, point-
of-care coagulation analyzers have been moved into the central laboratory – a
trained person runs the viscoelastic coagulation test and the results (evolving signa-
tures) are submitted real-time to the patient’s bedside.
Conclusion
Viscoelastic point-of-care coagulation analyzers are being used in certain clinical sit-
uations, especially in the management of patients undergoing cardiac and liver sur-
gery. Furthermore, they provide useful information in a large variety of clinical sce-
narios, e.g., massive hemorrhage, assessment of hypo- and hypercoagulable states,
and monitoring of pharmacological treatment with anti- and pro-coagulant agents.
The advantage of these techniques is that they have the potential to measure the
entire clotting process starting with fibrin formation and continuing through to clot
retraction and lysis at the bedside with minimal time delays. Furthermore, physio-
logical clot development is better depicted as a result of whole blood analysis of the
coagulation status. However, several problems regarding quality standards have to
be considered when using viscoelastic techniques.
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